Acute Lymphoblastic Leukemia News and Research RSS Feed - Acute Lymphoblastic Leukemia News and Research

Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells, the cells in the body that normally fight infections. There are two main types of white blood cells-lymphoid cells and myeloid cells. ALL affects lymphoid cells.
Researchers create first mouse model for common form of infant leukemia

Researchers create first mouse model for common form of infant leukemia

After nearly two decades of unsuccessful attempts, researchers from the University of Chicago Medicine and the Cincinnati Children's Hospital Medical Center have created the first mouse model for the most common form of infant leukemia. [More]
CHLA researchers receive TRP grant to study new way of combating relapsed ALL

CHLA researchers receive TRP grant to study new way of combating relapsed ALL

Yong-Mi Kim, MD, PhD, of The Saban Research Institute of Children's Hospital Los Angeles, has been awarded a 3 year translational research program grant from the Leukemia & Lymphoma Society to study a novel approach to eradicating minimal residual disease in patients with acute lymphoblastic leukemia (ALL). [More]
Researchers uncover possible targeted therapy for new, high-risk subtype of ALL

Researchers uncover possible targeted therapy for new, high-risk subtype of ALL

An international research team led by St. Jude Children's Research Hospital investigators has uncovered details of a new, high-risk subtype of acute lymphoblastic leukemia (ALL) as well as a possible targeted therapy. [More]
Study finds lack of improvement in health status of childhood cancer survivors

Study finds lack of improvement in health status of childhood cancer survivors

Long-term survivors of childhood cancer live longer thanks to improvements to cancer treatments, but a new study looking at three decades of therapy suggests patients do not report better health status. [More]
Combination of two drugs could be effective strategy to target T-cell lymphocytic leukemia

Combination of two drugs could be effective strategy to target T-cell lymphocytic leukemia

Researchers have determined that two Phase 1 drugs (CX-4945 and JQ1) can work together to efficiently kill T-cell acute lymphoblastic leukemia cells while having minimal impact on normal blood cells. [More]
NCCN publishes new resources to help patients understand treatment options for stomach cancer

NCCN publishes new resources to help patients understand treatment options for stomach cancer

This year, it is estimated that more than 26,000 people will be diagnosed with Stomach Cancer in the United States, with nearly one million new cases diagnosed worldwide each year. [More]
T-Bear brings hope to kids diagnosed with cancer at Seattle Children's Hospital

T-Bear brings hope to kids diagnosed with cancer at Seattle Children's Hospital

He may not be able to fly, or be as fast as the speed of light, but for children who have been diagnosed with cancer at Seattle Children's, the cuddly teddy bear who wears a mask and purple cape is still a super hero to them - he gives them strength. [More]
Scientists discover genomic alterations in pediatric relapsed ALL

Scientists discover genomic alterations in pediatric relapsed ALL

A group of researchers from Columbia University, Rutgers University, and institutions in Europe and Japan have identified genomic alterations in pediatric relapsed acute lymphoblastic leukemia (ALL) that cause both therapy resistance and improved clinical response to multi-agent chemotherapy treatment. [More]
Adolescent females have low rates of pregnancy screening prior to cancer treatment

Adolescent females have low rates of pregnancy screening prior to cancer treatment

A new study indicates that adolescent females with acute leukemia have low rates of pregnancy screening prior to receiving chemotherapy that can cause birth defects. [More]
Right dose of CAR T cells and lymphodepletion can achieve good response rates for NHL patients

Right dose of CAR T cells and lymphodepletion can achieve good response rates for NHL patients

In a paper published today in Science Translational Medicine, researchers from Fred Hutchinson Cancer Research Center shared data from an early-phase study of patients with advanced non-Hodgkin lymphoma (NHL) who received JCAR014, a Chimeric Antigen Receptor (CAR) T cell treatment, and chemotherapy. [More]
Novel conjugate therapy shows promise in destroying ALL cells with few side effects

Novel conjugate therapy shows promise in destroying ALL cells with few side effects

Researchers at UC Davis and Ionis Pharmaceuticals have developed a hybrid treatment that harnesses a monoclonal antibody to deliver antisense DNA to acute lymphoblastic leukemia (ALL) cells and that may lead to less toxic treatments for the disease. [More]
New study sheds light on pathogenesis of DNA lesions present in leukemia

New study sheds light on pathogenesis of DNA lesions present in leukemia

Researchers have succeeded in shedding light on the pathogenesis of DNA breakpoints that are associated with leukemia. [More]
Adaptive Biotechnologies demonstrates use of high-throughput sequencing platform for MRD

Adaptive Biotechnologies demonstrates use of high-throughput sequencing platform for MRD

Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, and collaborators will be presenting five studies demonstrating how Adaptive’s high-throughput sequencing platform enables diagnosis, detection and assessment of prognosis in hematological malignances and has increased sensitivity over flow cytometry. [More]
Discovery on new form ETV6-related thrombocytopenia presented at EHA Annual Congress

Discovery on new form ETV6-related thrombocytopenia presented at EHA Annual Congress

We recently discovered a new form of an inherited deficiency of platelets, which is caused by mutations in the ETV6-gene. [More]
Inotuzumab ozogamicin study reveals complete remission rates higher than standard therapy for ALL patients

Inotuzumab ozogamicin study reveals complete remission rates higher than standard therapy for ALL patients

In a randomized Phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with acute lymphoblastic leukemia (ALL) whose disease had relapsed following standard therapies, qualified for stem cell transplants. [More]
Higher blood levels of methotrexate impair executive functioning in long-term pediatric ALL survivors

Higher blood levels of methotrexate impair executive functioning in long-term pediatric ALL survivors

Research from St. Jude Children's Research Hospital suggests that pediatric leukemia patients exposed to higher concentrations of the chemotherapy drug methotrexate are more likely to struggle with mental flexibility, organization and related skills as long-term survivors. [More]
Neurotoxic effects of chemotherapy may impair cognitive function in young ALL patients

Neurotoxic effects of chemotherapy may impair cognitive function in young ALL patients

The neurotoxic effects of chemotherapeutic drugs on the developing brains of young patients with acute lymphoblastic leukemia (ALL) may impair their cognitive functioning by disrupting the formation of neural networks that connect brain regions and transfer information. [More]
Arkin Holdings and Primera Capital lead investment of $13M in BioSight

Arkin Holdings and Primera Capital lead investment of $13M in BioSight

BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity, announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabine™, for the treatment of AML. [More]
NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

It is estimated that more than 72,000 people in the United States will be diagnosed with Non-Hodgkin's Lymphomas (NHL) in 2016. The sixth leading cancer diagnosis in U.S. men and women, NHL has more than 30 sub-types, each featuring unique treatment choices and challenges. [More]
Experimental therapy has over 90% remission rate for advanced leukemia patients

Experimental therapy has over 90% remission rate for advanced leukemia patients

Twenty-seven of 29 patients with an advanced type of leukemia that had proved resistant to multiple other forms of therapy went into remission after their T cells (disease-fighting immune cells) were genetically engineered to fight their cancers. [More]
Advertisement